中药骨康对骨质疏松模型大鼠骨密度的影响  

Experimental Study on Gukang in Improving Bone Mineral Density of Rats with Osteoporosis

作　　者：黄杰文[1] 秦佳佳[2] 张素萍[1] 

机构地区：[1]广州中医药大学附属骨伤科医院,广东广州510240 [2]暨南大学医学院,广东广州510632

出　　处：《广州中医药大学学报》2009年第6期546-549,共4页Journal of Guangzhou University of Traditional Chinese Medicine

基　　金：暨南大学博士启动科研基金(编号:51205076)

摘　　要：【目的】观察中药骨康对骨质疏松模型大鼠骨密度的影响。【方法】选用雌性SD大鼠72只,随机分为6组,分别为假手术组,模型组,尼尔雌醇组(剂量为1 mg/kg),中药骨康高、中、低剂量组(中药高、中、低剂量组,剂量分别为9.6、4.8、2.4 g.kg-1.d-1)。采用双侧卵巢切除术复制骨质疏松模型,术后3个月各组分别按相应剂量给药,治疗3个月后取材,采用双能X线检测活体骨密度及离体左股骨、左胫骨骨密度。【结果】模型组活体全身及腰椎骨密度显著降低(P<0.05或P<0.01),中药高、中剂量组及尼尔雌醇组均可显著提高活体全身及腰椎骨密度(P<0.05或P<0.01)。模型组离体左股骨的整体、股骨头区(ROI 1)、股骨近端(ROI 2)、股骨远端(ROI 4)骨密度显著降低(P<0.05或P<0.01),中药高剂量组可显著提高整体及ROI 4的骨密度(P<0.05或P<0.01),中剂量组可显著提高ROI 4的骨密度(P<0.05)。模型组离体左胫骨的整体、胫骨近端(ROI 1)骨密度显著降低(P<0.01),中药高、中剂量组及尼尔雌醇组均可显著提高离体左胫骨的整体及ROI 1骨密度(P<0.05或P<0.01)。【结论】中药骨康治疗骨质疏松的作用可能与其能提高骨密度水平有关。Objective To observe the effect of Chinese medicine of Gukang （GK） on bone mineral density （BMD） in osteoporosis rats. Methods Seventy-two female SD rats were randomized into 6 groups： pseudooperation group, model group, nilestriol group （in the dose of l mg/kg） , and high-, middle- and low-dose GK groups （9. 6, 4. 8 and 2.4 g .kg^-1.d^-1 respectively）. Rat models of osteoporosis were induced by removal of bilateral ovaries. Three months after operation, the rats were given the corresponding medicine according the experimental design. After treatment for 3 months, in-vivo. BMD as well as the in-vitro BMD in the isolated left femur and tibia was detected with dual energy X-ray bone densitometer. Results The in-vivo general BMD and lumbar BMD of the model group were decreased （ P 〈 0. 05 or P 〈 0. 01 compared with the pseudo-operation group） , while were increased in high- and middle-dose GK groups and nilestriol group （ P 〈 0. 05 or P 〈 0. 01 compared with the model group ）. The in-vitro BMD in the isolated left whole femur, and in femoral head, proximal end and distal end of the isolated femur was decreased in the model group （ P 〈 0. 05 or P 〈 0.01 compared with the pseudo-operation group）. In high-dose GK group, in-vitro BMD in the while femur and in the distal end of the femur was increased （ P 〈 0. 05 or P 〈 0.01 compared with the model group） , and in-vitro BMD of the distal end of the femur in middle dose GK group was increased （P 〈 0. 05 ）. In-vitro BMD of the isolated left whole tibia and proximal end of the tibia was decreased in the model group （P 〈0. 01 compared with the pseudooperation group） , while was increased in high- and middle-dose GK groups and in nilestriol group （P 〈 0. 05 or P 〈0. 01 compared with the model group）. Conclusion The therapeutic mechanism of GK for the treatment of osteoporosis is probably related with the increase of BMD.

关 键 词：骨康/药理学 骨质疏松/中药疗法 骨密度 疾病模型 动物 大鼠 

分 类 号：R285.5[医药卫生—中药学]